Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
EuroChem is a leading global producer of nitrogen, phosphate and potash fertilizers, as well as certain industrial and mining products. The Group is vertically integrated with activities spanning mining to fertilizer production, logistics, and distribution. EuroChem began potash production at its Usolskiy mine in early 2018, and continues to develop a second greenfield site at VolgaKaliy in Russia. Headquartered in Zug, Switzerland, the Group operates production facilities in Europe, Asia and the CIS, employing more than 26,000 people.
hTTp://www.eurochemgroup.com/en/press-releases/eurochem-produces-first-test-product-at-usolskiy-potash-project/
hTTp://www.eurochemgroup.com/en/press-releases/eurochem-expands-further-in-brazil/
Potash miner Emmerson is close to inking a supply deal that could be worth as much as £4.4bn
https://www.thisismoney.co.uk/money/markets/article-6921627/Potash-miner-Emmerson-close-inking-supply-deal-worth-4-4bn.html
INITIAL 5 year deal RNSed today
Potash miner Emmerson is close to inking a supply deal that could be worth as much as £4.4bn
21:41, 14 April 2019
Potash miner Emmerson is close to inking a supply deal that could be worth as much as £4.4 billion over the next 20 years.
It has signed an initial agreement to provide a global fertiliser trader with all of the product from its Morocco-based mine for the next five years.
But the Mail understands it is in discussions to provide all of its potash to the international firm, which it has not named, for the next two decades.
Emmerson listed on the London Stock Exchange last year and has a current market value of £24 million.
It is understood that the international fertiliser trader is headquartered in Switzerland and has a large presence in Brazil.
hTTps://www.thisismoney.co.uk/money/markets/article-6921627/Potash-miner-Emmerson-close-inking-supply-deal-worth-4-4bn.html
Reports Results from Novel IPF Pre-Clinical Trial
RNS Number : 1394J
Nuformix PLC
03 December 2018
NXP002 out-performed current standard of care treatment, Esbriet ® (pirfenidone)
For info:
FDA approved Esbriet for treatment of idiopathic pulmonary fibrosis in 2014. The drug, whose revenue stood at $48 million in 2014, garnered nearly $856 million in 2017
First dosing of NXP001 took place successfully on 20 March 2019 in a cross-over study that aims to measure the relative bioavailability of NXP001 compared to Merck's EMEND® in healthy subjects. Dosing will complete during April 2019 with results expected by end H1 2019.
Worth noting that sales of Merck's EMEND totaled $556m in Merck's 2017 results
https://investors.merck.com/news/press-release-details/2018/Merck-Announces-Fourth-Quarter-and-Full-Year-2017-Financial-Results/default.aspx
Published today
https://www.youtube.com/watch?v=5QmQwCZV9P
CEO today conducted VOX market intervieew from Shanghai.
Obviously there to discuss progress of NXP001 with its Chinese partner Newsummit Biopharma.
Nuformix previously said it was in discussions with multiple parties regarding the marketing of the Rest of World rights for NXP001.
Nice write-up in todays Times market Report
Nuformix has £51m in the pot
A Cambridge-based drugs company has struck a deal worth up to £51 million for the development, licensing and commercialisation of cannabinoid drugs for therapeutic uses.
Shares in Nuformix surged by 25 per cent to 3½p yesterday after it announced the agreement with Ebers Tech, a private Canadian company.
Nuformix specialises in tweaking existing drugs for new applications. It uses “co-crystallisation” technology that can alter an existing drug to improve its performance.
The deal with Ebers Tech is focused on cannabinoids, found in cannabis, and on uses such as treating pain or side-effects of chemotherapy.
The agreement entails up to £51 million of research and development and milestone payments, plus royalties of 20 per cent of net sales. Nuformix will be responsible for early research and development. Ebers will handle “late-stage development, clinical programmes and commercialisation”.
Dan Gooding, chief executive of Nuformix, said: “In Ebers, we have a partner in the ideal location for maximising value in the emerging cannabinoids market.”
https://www.thetimes.co.uk/edition/business/labour-government-risks-sending-water-downhill-vdlsj3vc3
BIDS
"We believe this strategy will result in the business being well placed to meet market expectations for 2019 and will facilitate extensive growth in 2020. As a fast-growing business, we expect that revenues in 2019 will be significantly second half weighted with perhaps a more marked split than previously anticipated."
EMLteam touching down for the @UKInvestorShow show tomorrow. Come and meet the team at Stall 12 and watch CEO @HaydenLocke5 present the low cost, high margin Khemisset project at 11.20 in the Wray Room. Watch the video below for a teaser of our 2019 plans...
https://twitter.com/emmerson_plc/status/1111653911138570242
Stockwatch: Put this AIM share on your radar
This is a fast-growing technology business, and some believe the share price could double.
Is £60 million AIM-listed "alternative supplier of superfast broadband" Bigblu Broadband (LSE:BBB) achieving genuine critical mass, which could potentially be appealing to a larger telecoms group? And is it also at a genuine inflection point into earnings growth, like its broker Numis proclaims?
continues...
https://www.ii.co.uk/analysis-commentary/stockwatch-put-aim-share-your-radar-ii507966
Yourgene – Egypt “news” in the loosest term: Strong Buy
By HotStockRockets | Tuesday 26 March 2019
It is hard to get terribly excited by the latest news from Yourgene (YGEN). Indeed is it really news? But fear not there is far more exciting material in the pipeline...
https://www.*************.com/views/41709/yourgene-egypt-news-in-the-loosest-term-strong-buy
19th March 2019Emmerson (EML) Share ViewsRuntime 16:48
Hayden Locke, the CEO of Emmerson plc spoke to London South East about the Khemisset Potash project in Northern Morocco.
Potash is the name used to describe agricultural fertiliser with a high concentration of potassium in it, with most produced in Canada, Russia and Belarus.
The main markets are what you might expect: China, who have their own mines, the US, Brazil and Western Europe. Morocco imports fertilizer currently and its needs are growing. If you take Brazil for example, the delivered to the market price is $360 per tonne. According to Hayden, very few potash mines are developed from scratch as the capital costs can be very high - as much as $4 billion.
At a projected cost of just $400 million CAPEX he says this makes Khemisset a snip and much lower cost than its peers. And there are only 2 listed potash miners on the Junior market for you to invest in. When taking the delivered to market costs Khemisset is in the bottom quartile of costs, so potentially very competitive and close to its end markets of Brazil, North West Europe, the US, SA and Morocco.
Hayden says the business already has between $3-4 million dollars on its balance sheet and needs say $5M to get them to the point of raising the larger sum through a mix of debt, equity and industry funding.
http://www.lse.co.uk/media/exclusive-hayden-locke-ceo-emmerson-plc-a-low-cost-high-margin-potash-investment.html
Positive write up today in Proactiveinvestors . co .uk
Probably wont be able to link so here are a few extracts
“This market is going to explode and we are very well placed”
=====================================================
Having already agreed a deal with Thermo Fisher, another gene sequencing giant, in 2014, the settlement gave Yourgene a foothold on the platforms that account for 90% of sample testing globally.
That presence should not be underestimated, says Rees.
“We go to customers and say we are on either.”
That relationship with Illumina is now fantastic, he adds, and more importantly, rather than being in court, Yourgene’s management can focus on growing the company.
==================================================
The number of IONA tests carried out in the six months to September, jumped by 73% to 38,000, while revenues rose 45% to £3.9mln.
But that is only scratching the surface, believes Rees.
=================================================
Numbers of tests rising in emerging markets
And adoption of NIPT is growing rapidly.
In the Netherlands for example, all pregnancies are now screened.
Here in the UK, moves are underway to screen all high-risk births and eventually it seems likely the NHS will adopt a similar policy.
At a cost of between £300-600 for an NIPT, the private sector is also an option.
=========================================================
In December, Rees said he expects this current half year to be its strongest half to date and Yourgene will enter the new financial year effectively debt-free, with no distractions from litigation.
“This market is going to explode and we are very well placed.”
Sorry , Strongman.
Strong, hope you don't mind - I reposted TIm Sykes reply onto A-D-V-F-N PHD bb.
Further to PEPPOL , PHD access via recent acquisition Esize Holdings
Esize is certified PEPPOL Access Point provider
Esize, part of Proactis - supplier of Spend Management and B2B eCommerce solutions, is now officially certified as a PEPPOL Access Point Provider . This means that Esize itself can connect customers to the European e-invoicing network PEPPOL to exchange digital invoices with OpenPEPPOL members. With this, Esize is taking an important step towards safer, more efficient and more sustainable invoicing in the Netherlands and the rest of Europe. PEPPOL is already being used by more than 10,000 organizations, and this number is growing every day. Governments in Europe already use PEPPOL to a large extent and it is expected that more and more companies will join.
continues..
https://translate.google.com/translate?hl=en&sl=nl&u=https://www.esize.com/nl/esize-is-gecertifieerd-peppol-access-point-provider/&prev=search